Buchumschlag

Improving CORM technology for the treatment of delayed hemolytic transfusion reaction

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Michela Asperti, Francesca Vinchi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

News on sickle cell disease: Heme‐driven disordered erythropoiesis
von: Francesca Vinchi
Veröffentlicht: (2024)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
von: Francesca Vinchi, et al.
Veröffentlicht: (2024)

How I manage luspatercept in transfusion‐dependent beta‐thalassemia
von: Daniele Lello Panzieri, et al.
Veröffentlicht: (2026)

Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
von: Khaled M. Musallam, et al.
Veröffentlicht: (2025)

Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
von: Monika Dzieciatkowska, et al.
Veröffentlicht: (2026)

Hypomorphic ATP11c is a novel regulator of decreased efficacy of transfused red blood cells in humans and mice
von: James C. Zimring, et al.
Veröffentlicht: (2026)

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
von: Anna Maria Frustaci, et al.
Veröffentlicht: (2025)

Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma
von: Sirpa Leppä, et al.
Veröffentlicht: (2025)

Fitusiran treatment modulates the ratio between alpha‐ and beta‐antithrombin isoforms
von: Geneviève McCluskey, et al.
Veröffentlicht: (2026)

Quality of vitamin K antagonist treatment during the last year of life
von: Chantal Visser, et al.
Veröffentlicht: (2025)

European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review
von: Francesca Fioredda, et al.
Veröffentlicht: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Veröffentlicht: (2025)

Metabolism in hematology: Technological advances open new perspectives on disease biology and treatment
von: Eileen Haring, et al.
Veröffentlicht: (2025)

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities
von: Emma Kroeze, et al.
Veröffentlicht: (2024)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
von: Johannes Steinhart, et al.
Veröffentlicht: (2024)

Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry
von: Inés Gómez‐Seguí, et al.
Veröffentlicht: (2025)

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose‐reduction better for all?
von: Mandy N. Lauw, et al.
Veröffentlicht: (2026)

HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
von: Charles Toulemonde, et al.
Veröffentlicht: (2025)

Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
von: Angela Consagra, et al.
Veröffentlicht: (2025)

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
von: Thomas Chatzikonstantinou, et al.
Veröffentlicht: (2024)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
von: Uwe Platzbecker, et al.
Veröffentlicht: (2025)

Machine learning enhances risk stratification and treatment failure prediction in diffuse large B‐cell lymphoma
von: Mikkel Werling, et al.
Veröffentlicht: (2026)

Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
von: Catherine Thieblemont, et al.
Veröffentlicht: (2025)

Additive effect of multiple genetic variants in SEC23B and PIEZO1 on iron metabolism dyshomeostasis in hereditary anemias
von: Antonella Nostroso, et al.
Veröffentlicht: (2026)

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study
von: Marcus Hentrich, et al.
Veröffentlicht: (2024)

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
von: Andrés J. M. Ferreri, et al.
Veröffentlicht: (2024)

Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up
von: Kai Hübel, et al.
Veröffentlicht: (2024)

Correction to “Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up”
Veröffentlicht: (2025)

Peripheral T‐ and natural killer‐cell lymphomas: ESMO‐EHA Clinical Practice Guideline for diagnosis, treatment, and follow‐up
von: Francesco d'Amore, et al.
Veröffentlicht: (2025)

Integration of gene mutations in risk prognostication for watch‐and‐wait follicular lymphoma patients initiating first‐line treatment
von: Tian‐Yuan Xu, et al.
Veröffentlicht: (2025)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
von: Arnon P. Kater, et al.
Veröffentlicht: (2024)

Correction to “Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up”
Veröffentlicht: (2024)

Parents' perception of treatment‐related toxicity in children treated according to the NOPHO ALL2008 protocol for acute lymphoblastic leukemia
von: Nina Mogensen, et al.
Veröffentlicht: (2024)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Veröffentlicht: (2025)

Efficacy and safety of steroid‐sparing strategy in the treatment of AIHA associated with KSHV/HHV‐8 positive multicentric Castleman disease
von: Yannick Dieudonné, et al.
Veröffentlicht: (2026)

Intra‐subtype heterogeneity shapes treatment response in KMT2A ‐rearranged ALL across all age groups
von: Alina M. Hartmann, et al.
Veröffentlicht: (2026)

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
von: Paolo Ghia, et al.
Veröffentlicht: (2025)

Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
von: Claire N. Harrison, et al.
Veröffentlicht: (2025)

Outcomes and treatment patterns of patients with primary mediastinal B‐cell lymphoma after CAR‐T cell therapy failure: A DESCAR‐T analysis
von: Jean Galtier, et al.
Veröffentlicht: (2025)

Serum TARC dynamics during anti‐PD1‐based first‐line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
von: Wouter J. Plattel, et al.
Veröffentlicht: (2025)